Neal JW - Search Results

1

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. Chabon JJ, et al. Among authors: neal jw. Nat Commun. 2016 Jun 10;7:11815. doi: 10.1038/ncomms11815. Nat Commun. 2016. PMID: 27283993 Free PMC article.

2

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.

Neal JW, Sequist LV. Neal JW, et al. Nat Rev Clin Oncol. 2010 Feb;7(2):71-2. doi: 10.1038/nrclinonc.2009.191. Nat Rev Clin Oncol. 2010. PMID: 20118973 No abstract available.

3

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

Neal JW, Sequist LV. Neal JW, et al. Clin Adv Hematol Oncol. 2010 Feb;8(2):119-26. Clin Adv Hematol Oncol. 2010. PMID: 20386533 Review.

4

Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.

Neal JW, Sequist LV. Neal JW, et al. Curr Treat Options Oncol. 2010 Jun;11(1-2):36-44. doi: 10.1007/s11864-010-0120-6. Curr Treat Options Oncol. 2010. PMID: 20676809 Review.

5

AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer.

Neal J, Wakelee H. Neal J, et al. Curr Opin Mol Ther. 2010 Aug;12(4):487-95. Curr Opin Mol Ther. 2010. PMID: 20677100

6

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Neal JW, et al. J Thorac Oncol. 2010 Nov;5(11):1855-8. doi: 10.1097/JTO.0b013e3181f0bee0. J Thorac Oncol. 2010. PMID: 20975380 Free article. Clinical Trial.

7

Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV. Mak RH, et al. Among authors: neal jw. Oncologist. 2011;16(6):886-95. doi: 10.1634/theoncologist.2011-0040. Epub 2011 May 31. Oncologist. 2011. PMID: 21632451 Free PMC article.

8

Current management of small cell lung cancer.

Neal JW, Gubens MA, Wakelee HA. Neal JW, et al. Clin Chest Med. 2011 Dec;32(4):853-63. doi: 10.1016/j.ccm.2011.07.002. Epub 2011 Sep 28. Clin Chest Med. 2011. PMID: 22054891 Review.

9

Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

Neal JW, Sequist LV. Neal JW, et al. J Clin Oncol. 2012 Jun 20;30(18):2280-2. doi: 10.1200/JCO.2011.41.0860. Epub 2012 Apr 16. J Clin Oncol. 2012. PMID: 22508823 No abstract available.

10

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.

Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. Goldberg SB, et al. Among authors: neal jw. J Thorac Oncol. 2012 Oct;7(10):1602-8. doi: 10.1097/JTO.0b013e318262de4a. J Thorac Oncol. 2012. PMID: 22878749 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

340 results

Search Page

Filters